Parkinson's Disease News and Research

Latest Parkinson's Disease News and Research

New research shows migraine and depression may share common genetic pathways

New research shows that migraine and depression may share a strong genetic component. The research is published in the January 13, 2010, online issue of Neurology®, the medical journal of the American Academy of Neurology.

18 Jan 2010

Karolinska Development AB and BioChromix AB form BioChromix Pharma AB

Karolinska Development AB (publ), and BioChromix AB announced today the formation of BioChromix Pharma AB, a new company working to develop a novel Alzheimer treatment with its unique knowledge of molecular chemistry. Karolinska Development will initially take 28 percent ownership in the new company.

18 Jan 2010

Study reveals interaction of genetic and environmental factors in the pathogenesis of Parkinson's disease

"Our study reveals the interaction of genetic and environmental factors such as dietary habits in the pathogenesis of Parkinson's disease," explained Dr. Matthias Elstner of the Neurological Clinic of LMU and Helmholtz Zentrum M-nchen, lead author of the study.

18 Jan 2010

Inadequate saliva and fluoride can contribute to tooth decay

Tooth enamel is tough, harder even than skeletal bone. But even with good dental hygiene, the enamel protecting teeth may show signs of decay in older adults. The January issue of Mayo Clinic Health Letter covers what to look out for and what to do to promote an enamel-friendly setting in the mouth. According to the newsletter, two significant contributors to tooth decay are too little saliva and inadequate fluoride.

18 Jan 2010

Dartmouth researchers to develop and market a drug throughout Asia for treatment of CKD

Thanks in part to more than a decade of preclinical work by Dartmouth researchers, a Japanese biopharmaceutical firm is preparing to develop and market throughout Asia a drug for the treatment of chronic kidney disease (CKD).

18 Jan 2010

MediSens Wireless to begin its wireless body-monitoring system clinical trials following FDA approval

MediSens Wireless, a startup company in UCLA's on-campus technology incubator at the California NanoSystems Institute, has obtained approval under federal Food and Drug Administration guidelines to begin clinical trials on its novel wireless body-monitoring system, which assesses muscle and neuromotor functions in the upper extremities.

18 Jan 2010

New findings may yield novel therapies for chronic neurodegenerative diseases

We all have at one time or another experienced the typical signs of an infection: the fever, the listlessness, the lack of appetite. They are orchestrated by the brain in response to circulating cytokines, the signaling molecules of the immune system. But just how cytokines' reach extends beyond the almost impenetrable blood-brain barrier has been the topic of much dispute.

18 Jan 2010

Zassi Medical Evolutions forms new company to develop electrical stimulation technology

Zassi Medical Evolutions, a privately held organization that innovates, designs and develops high technology medical devices and software announced today that it has successfully spun out and formed a new company with Tucson, Arizona based Research Corporation Technologies (RCT) to pursue the continued development of a novel electrical stimulation technology for the gastrointestinal continence control market.

13 Jan 2010

PIMs usage among elderly patients may increase adverse events and health care costs

A new study provides important evidence that the use of certain potentially inappropriate medications (PIMs) among the elderly may increase adverse events and health care costs.

13 Jan 2010

Olfactory dysfunction may serve as an early diagnostic tool for Alzheimer's disease

A study published in the January 13, 2010 issue of the Journal of Neuroscience links a loss of smell function in Alzheimer's disease (AD) model animals with amyloid β (protein) accumulation in the brain, a distinguishing hallmark of Alzheimer's disease. Research conducted by NYU Langone Medical Center suggests that olfactory dysfunction, a common symptom of AD, may serve as an early diagnostic tool for the disease.

13 Jan 2010

MedGenesis Therapeutix enters into license agreement with Amgen

MedGenesis Therapeutix Inc. ("MedGenesis"), a biopharmaceutical company developing and commercializing innovative treatments for patients with serious central nervous system (CNS) diseases, announced today that it has successfully entered into an agreement with Amgen Inc. ("Amgen"), granting MedGenesis an exclusive, worldwide license for glial cell line-derived neurotrophic factor (GDNF) protein in CNS and non-CNS indications, subject to the rights of a co-exclusive licensee for CNS indications in certain countries, as further described below.

12 Jan 2010

Reducing DA dosage causes acute withdrawal symptoms in Parkinson's patients

New research has shown that reducing the dosage of dopamine agonist (DA) drugs, a mainstay treatment for Parkinson's disease (PD), sometimes causes acute withdrawal symptoms similar to those reported by cocaine addicts -- including anxiety, panic attacks, depression, sweating, nausea, generalized pain, fatigue, dizziness and drug cravings. These symptoms can be severe, and are not alleviated by other PD medications.

12 Jan 2010

Amicus Therapeutics presents corporate outlook for 2010 at Annual J.P. Morgan Healthcare Conference

Amicus Therapeutics today outlined the Company's three key strategic priorities and presented a corporate outlook for 2010 at the 28th Annual J.P. Morgan Healthcare Conference.

12 Jan 2010

DSG teams up with pharmaceutical technology company to speed early detection of major diseases

DSG, a leader in electronic data capture (EDC) has teamed up with a leading-edge pharmaceutical technology company to speed the early detection of Alzheimer’s, Parkinson’s, and Diabetes.

12 Jan 2010

Sangamo BioSciences initiates two new clinical trials of ZFP Therapeutics

Sangamo BioSciences, Inc. announced the initiation of two new clinical trials of ZFP Therapeutics, a Phase 2b study in diabetic neuropathy (DN) and a Phase 1 trial in glioblastoma, as well as the renewal of $3.0 million in funding for the Phase 2b trial by the Juvenile Diabetes Research Foundation International (JDRF).

11 Jan 2010

Neurosurgeons perform world's first operation on 'habenula' to treat depression

A team of neurosurgeons at Heidelberg University Hospital and psychiatrists at the Central Institute of Mental Health, Mannheim have for the first time successfully treated a patient suffering from severe depression by stimulating the habenula, a tiny nerve structure in the brain.

8 Jan 2010

VA expected to move soon to cover more effects of Agent Orange

The Department of Veterans Affairs may need to pay heavily to treat veterans who have been adversely affected by Agent Orange. McClatchy/Beaufort (S.C.) Gazette report: "The cost of war -- on veterans' health and taxpayer wallets -- will loom a little larger in the new year when the Department of Veterans Affairs issues a final rule to claim adjudicators to presume three more diseases of Vietnam veterans, including heart disease, were caused by exposure to Agent Orange.

8 Jan 2010

Chinese researchers become the world's fifth most prolific contributors to regenerative medicine

Chinese researchers have become the world's fifth most prolific contributors to peer-reviewed scientific literature on clock-reversing regenerative medicine even as a skeptical international research community condemns the practice of Chinese clinics administering unproven stem cell therapies to domestic and foreign patients.

8 Jan 2010

Scientists identify gene underlying a disease that causes temporary paralysis of skeletal muscle

Scientists have identified a gene underlying a disease that causes temporary paralysis of skeletal muscle. The finding, they say, illustrates how investigations of rare genetic diseases can drive insights into more common ones.

8 Jan 2010

Proteostasis Therapeutics enters into exclusive license agreement with New York University

Proteostasis Therapeutics announced today that it has entered into an exclusive license agreement with New York University for intellectual property related to discoveries from the laboratory of David Ron, M.D., Professor of Medicine and Julius Raynes Professor of Cell Biology at NYU Langone Medical Center’s Skirball Institute of Biomolecular Medicine.

8 Jan 2010

Parkinson's Disease News and Research

Latest Parkinson's Disease News and Research

New research shows migraine and depression may share common genetic pathways

Karolinska Development AB and BioChromix AB form BioChromix Pharma AB

Study reveals interaction of genetic and environmental factors in the pathogenesis of Parkinson's disease

Inadequate saliva and fluoride can contribute to tooth decay

Dartmouth researchers to develop and market a drug throughout Asia for treatment of CKD

MediSens Wireless to begin its wireless body-monitoring system clinical trials following FDA approval

New findings may yield novel therapies for chronic neurodegenerative diseases

Zassi Medical Evolutions forms new company to develop electrical stimulation technology

PIMs usage among elderly patients may increase adverse events and health care costs

Olfactory dysfunction may serve as an early diagnostic tool for Alzheimer's disease

MedGenesis Therapeutix enters into license agreement with Amgen

Reducing DA dosage causes acute withdrawal symptoms in Parkinson's patients

Amicus Therapeutics presents corporate outlook for 2010 at Annual J.P. Morgan Healthcare Conference

DSG teams up with pharmaceutical technology company to speed early detection of major diseases

Sangamo BioSciences initiates two new clinical trials of ZFP Therapeutics

Neurosurgeons perform world's first operation on 'habenula' to treat depression

VA expected to move soon to cover more effects of Agent Orange

Chinese researchers become the world's fifth most prolific contributors to regenerative medicine

Scientists identify gene underlying a disease that causes temporary paralysis of skeletal muscle

Proteostasis Therapeutics enters into exclusive license agreement with New York University

Human iPSCs: A Full Guide to Advanced in Vitro Models and Applications eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Parkinson's Disease News and Research

Latest Parkinson's Disease News and Research

Human iPSCs: A Full Guide to Advanced in Vitro Models and Applications eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Newsletters you may be interested in